Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models

Lignende værker

• Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779
  af: Messina, Michael P, et al.
  Udgivet: (2007)
• Comparison of three rapamycin dosing schedules in A/J Tsc2(+/- )mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors
  af: Woodrum, Chelsey, et al.
  Udgivet: (2010)
• Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
  af: Rauktys, Aubrey, et al.
  Udgivet: (2008)
• Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats
  af: Karbownik, Agnieszka, et al.
  Udgivet: (2020)
• Multicenter prospective study of treatment of Brucella melitensis brucellosis with doxycycline for 6 weeks plus streptomycin for 2 weeks.
  af: Cisneros, J M, et al.
  Udgivet: (1990)